PortalPublikationenInfliximab as a rescue treatment in difficult-to-treat autoi...

Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis.

Standard

Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. / Weiler-Normann, Christina; Schramm, Christoph; Quaas, Alexander; Wiegard, Christiane; Glaubke, Claudia; Pannicke, Nadine; Hübener, Sina; Lohse, Ansgar W.

in: J HEPATOL, Jahrgang 58, Nr. 3, 3, 2013, S. 529-534.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Weiler-Normann, C, Schramm, C, Quaas, A, Wiegard, C, Glaubke, C, Pannicke, N, Hübener, S & Lohse, AW 2013, 'Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis.', J HEPATOL, Jg. 58, Nr. 3, 3, S. 529-534. https://doi.org/10.1016/j.jhep.2012.11.010

APA

Weiler-Normann, C., Schramm, C., Quaas, A., Wiegard, C., Glaubke, C., Pannicke, N., Hübener, S., & Lohse, A. W. (2013). Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J HEPATOL, 58(3), 529-534. [3]. https://doi.org/10.1016/j.jhep.2012.11.010

Vancouver

Weiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J HEPATOL. 2013;58(3):529-534. 3. https://doi.org/10.1016/j.jhep.2012.11.010

Bibtex

@article{d8febae063e04e7c880dcc6e3550e0f3,
title = "Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis.",
abstract = "BACKGROUND & AIMS: Autoimmune hepatitis is a chronic inflammatory liver disease that leads to liver cirrhosis and corresponding complications, if left untreated. Current standard treatment with azathioprine and prednisolone induces remission in the vast majority of patients. However, for those patients not responding to standard treatment or not tolerating these drugs, few alternatives can be used and their effectiveness might be limited. We sought to analyze the safety and efficacy of off-label treatment with infliximab in a cohort of eleven patients with difficult-to-treat autoimmune hepatitis.METHODS: Patients with difficult-to-treat autoimmune hepatitis who could not be brought into remission with standard treatment, either due to drug intolerance or to insufficient drug impact, were treated off-label with infliximab for a minimum of six months. Patient files were reviewed retrospectively.RESULTS: Treatment with infliximab led to reduction of inflammation, evidenced by a decrease in transaminases (mean AST prior treatment 475 U/L ± 466, mean AST during treatment 43 U/L ± 32) as well as in immunoglobulins (pretreatment mean IgG 24.8 mg/dl ± 10.1, mean IgG during treatment 17.38 mg/dl ± 6). Infectious complications occurred in seven out of eleven patients and close monitoring was necessary.CONCLUSIONS: Infliximab may be considered as rescue therapy in patients with difficult-to-treat autoimmune hepatitis, albeit treatment may be associated with infectious complications.",
keywords = "Adult, Aged, Alanine Transaminase, Antibodies, Monoclonal, Female, Hepatitis, Autoimmune, Humans, Immunoglobulin G, Male, Middle Aged, Retrospective Studies, Tumor Necrosis Factor-alpha",
author = "Christina Weiler-Normann and Christoph Schramm and Alexander Quaas and Christiane Wiegard and Claudia Glaubke and Nadine Pannicke and Sina H{\"u}bener and Lohse, {Ansgar W}",
note = "Copyright {\textcopyright} 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.",
year = "2013",
doi = "10.1016/j.jhep.2012.11.010",
language = "English",
volume = "58",
pages = "529--534",
journal = "J HEPATOL",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis.

AU - Weiler-Normann, Christina

AU - Schramm, Christoph

AU - Quaas, Alexander

AU - Wiegard, Christiane

AU - Glaubke, Claudia

AU - Pannicke, Nadine

AU - Hübener, Sina

AU - Lohse, Ansgar W

N1 - Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

PY - 2013

Y1 - 2013

N2 - BACKGROUND & AIMS: Autoimmune hepatitis is a chronic inflammatory liver disease that leads to liver cirrhosis and corresponding complications, if left untreated. Current standard treatment with azathioprine and prednisolone induces remission in the vast majority of patients. However, for those patients not responding to standard treatment or not tolerating these drugs, few alternatives can be used and their effectiveness might be limited. We sought to analyze the safety and efficacy of off-label treatment with infliximab in a cohort of eleven patients with difficult-to-treat autoimmune hepatitis.METHODS: Patients with difficult-to-treat autoimmune hepatitis who could not be brought into remission with standard treatment, either due to drug intolerance or to insufficient drug impact, were treated off-label with infliximab for a minimum of six months. Patient files were reviewed retrospectively.RESULTS: Treatment with infliximab led to reduction of inflammation, evidenced by a decrease in transaminases (mean AST prior treatment 475 U/L ± 466, mean AST during treatment 43 U/L ± 32) as well as in immunoglobulins (pretreatment mean IgG 24.8 mg/dl ± 10.1, mean IgG during treatment 17.38 mg/dl ± 6). Infectious complications occurred in seven out of eleven patients and close monitoring was necessary.CONCLUSIONS: Infliximab may be considered as rescue therapy in patients with difficult-to-treat autoimmune hepatitis, albeit treatment may be associated with infectious complications.

AB - BACKGROUND & AIMS: Autoimmune hepatitis is a chronic inflammatory liver disease that leads to liver cirrhosis and corresponding complications, if left untreated. Current standard treatment with azathioprine and prednisolone induces remission in the vast majority of patients. However, for those patients not responding to standard treatment or not tolerating these drugs, few alternatives can be used and their effectiveness might be limited. We sought to analyze the safety and efficacy of off-label treatment with infliximab in a cohort of eleven patients with difficult-to-treat autoimmune hepatitis.METHODS: Patients with difficult-to-treat autoimmune hepatitis who could not be brought into remission with standard treatment, either due to drug intolerance or to insufficient drug impact, were treated off-label with infliximab for a minimum of six months. Patient files were reviewed retrospectively.RESULTS: Treatment with infliximab led to reduction of inflammation, evidenced by a decrease in transaminases (mean AST prior treatment 475 U/L ± 466, mean AST during treatment 43 U/L ± 32) as well as in immunoglobulins (pretreatment mean IgG 24.8 mg/dl ± 10.1, mean IgG during treatment 17.38 mg/dl ± 6). Infectious complications occurred in seven out of eleven patients and close monitoring was necessary.CONCLUSIONS: Infliximab may be considered as rescue therapy in patients with difficult-to-treat autoimmune hepatitis, albeit treatment may be associated with infectious complications.

KW - Adult

KW - Aged

KW - Alanine Transaminase

KW - Antibodies, Monoclonal

KW - Female

KW - Hepatitis, Autoimmune

KW - Humans

KW - Immunoglobulin G

KW - Male

KW - Middle Aged

KW - Retrospective Studies

KW - Tumor Necrosis Factor-alpha

U2 - 10.1016/j.jhep.2012.11.010

DO - 10.1016/j.jhep.2012.11.010

M3 - SCORING: Journal article

C2 - 23178709

VL - 58

SP - 529

EP - 534

JO - J HEPATOL

JF - J HEPATOL

SN - 0168-8278

IS - 3

M1 - 3

ER -